The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
84
Fortrea Clinical Research Unit
Madison, Wisconsin, United States
RECRUITINGLilly Centre for Clinical Pharmacology
Singapore, Singapore
RECRUITINGNumber and Incidence of Serious Adverse Events (SAEs)
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to study completion (up to 29 weeks)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax)
PK: Cmax of LY4167586
Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)
PK: Time of Maximum Drug Concentration (tmax)
PK: tmax of LY4167586
Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)
PK: Area Under the Concentration Versus Time Curve (AUC)
PK: AUC of LY4167586
Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.